Figure S3 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer

Key Points

• Comparative results reveal differences in T-cell activation markers between treated and untreated conditions.
• T-cell activation was significantly higher in patients receiving anti-PD-1 therapy, suggesting improved immune response.
• Assessment of treatment effects was conducted using patient-derived tumor fragments (PDTFs) as a novel model.
• Findings highlight the need for personalized therapies over traditional one-size-fits-all approaches.